Jazz Pharmaceuticals (JAZZ) FY2019 results: revenue $2.2 billion, up 14.3% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $2.2 billion for fiscal 2019, the year ended 31 December 2019, up 14.3% on the year before. Net income was $523 million, up 17.1%, and diluted earnings per share $9.09. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2020.
Revenue
$2.2 billion
+14.3% on the year
FY2012FY2019
Operating margin
24.6%
32.5% a year earlier
FY2012FY2019
Net income
$523 million
+17.1% on the year
FY2012FY2019
Diluted EPS
$9.09
+24.5% on the year
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
2,162
1,891
1,619
+14.3%
Research and development
300
227
198
+32.3%
Selling, general and administrative
737
684
544
+7.8%
Operating income
532
615
529
-13.4%
Operating margin
24.6%
32.5%
32.7%
Interest expense
62.5
56.7
37.8
+10.2%
Pre-tax income
454
529
441
-14.2%
Income tax
-73.2
80.2
-47.7
Effective tax rate
-16.1%
15.1%
-10.8%
Net income
523
447
488
+17.1%
Net margin
24.2%
23.6%
30.1%
Diluted EPS
$9.09
$7.30
$7.96
+24.5%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
776
799
693
-2.8%
Capital expenditure
40.1
20.4
28.9
+97.0%
Free cash flow
736
779
664
-5.4%
Free cash flow margin
34.1%
41.2%
41.0%
Cash from investing
-155
-394
-269
Cash from financing
-294
-479
-409
Depreciation and amortisation
15.3
15.2
13.1
+0.7%
Share-based compensation
111
102
107
+7.9%
Buybacks
301
524
98.8
-42.4%
Diluted shares, weighted
58m
61m
61m
-6.0%
Shares outstanding at period end
56m
58m
60m
-2.4%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
3,111
2,757
2,713
+12.8%
Debt
1,607
1,596
1,581
+0.7%
Operating lease liabilities
151
0.0
n/a
Other liabilities
669
850
830
-21.2%
Total liabilities and equity
5,539
5,203
5,124
+6.4%
Fixed assets
132
200
170
-34.4%
Goodwill
920
928
948
-0.8%
Intangible assets
2,441
2,731
2,979
-10.6%
Securities held for sale or to maturity
1,077
825
601
+30.6%
Cash and equivalents
637
310
386
+105.8%
Receivables
356
264
224
+34.9%
Inventory
78.6
53.0
43.2
+48.4%
Total assets
5,539
5,203
5,124
+6.4%
10-K for the year ended 31 December 2019, filed 25 February 2020: the filing.